Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06059664 · ClinicalTrials.gov registry record · Phase 2
The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study
A Phase 2 study of Kidney Transplant; Complications, sponsored by University of North Carolina, Chapel Hill.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 150
- Enrollment target
- 1
- Study location
NCT06059664: Recruiting Phase 2 study of Kidney Transplant; Complications, sponsored by University of North Carolina, Chapel Hill.
NCT06059664 is a Phase 2 study of Kidney Transplant; Complications that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 150 participants, above the 114-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (32% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06059664, a Phase 2 study of Kidney Transplant; Complications, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 150 participants
- Enrollment target
- 1
- Study location
Study Summary
EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a 2:1 ratio of finerenone to placebo, with two embedded substudies: (i) a kidney biopsy substudy in 50 participants who undergo a research kidney biopsy prior to randomization and at the end of active treatment; and (ii) a functional MRI (fMRI) substudy in 50 participants who undergo fMRI prior to randomization and at the end of active treatment.
Primary Outcome
Signed consent by 30 participants for the main clinical trial within 3 months of launching the full study protocol (date of first person randomized).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Finerenone Oral Tablet
Study Locations (1)
North Carolina
- UNC Eastowne Kidney Transplant Clinic - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2024-04-23 |
| Est. Completion | 2027-09-30 |
| Phase | Phase 2 |
What NCT06059664 shows while recruiting
NCT06059664 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, above the 114-participant average among 19 other Kidney Transplant; Complications trials with a reported enrollment target (32% higher).
The record links to 1 condition, with Kidney Transplant; Complications appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06059664 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT06059664 about?
NCT06059664 is a clinical study titled "The EFfect of FinErenone in Kidney TransplantiOn Recipients: The EFFEKTOR Study". EFFEKTOR is a vanguard, multicenter, phase 2 randomized, double blinded, placebo controlled clinical trial to determine the feasibility, tolerability, safety, and efficacy of finerenone in kidney transplant recipients (KTRs). One hundred fifty (150) KTRs will be randomized in a 2:1 ratio of finereno...
What is the current status of trial NCT06059664?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2024-04-23. Estimated completion is 2027-09-30.
What conditions does trial NCT06059664 study?
This clinical trial studies the following conditions: Kidney Transplant; Complications.
What interventions are being tested in trial NCT06059664?
The interventions under investigation include: Placebo (DRUG), Finerenone Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06059664?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06059664 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant; Complications
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06059664's enrollment target sits among peer trials
150 5th of 19 higher than 15 of 19 other Kidney Transplant; Complications trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Transplant; Complications trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Immune Registry for BK in Kidney Transplant Recipients
RECRUITING
-
Feasibility Study for the Comprehensive Overweight/Obesity Management Pre-Kidney Transplant (COMPKT) Program
RECRUITING · NA
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
RECRUITING · Phase 4
-
Dietary Intervention to Improve Kidney Transplant Outcomes
RECRUITING · NA
-
Double Voiding and Post-transplant UTI
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00412594 · 150 participants · Phase 2
Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia
- NCT01484730 · 150 participants
A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion
- NCT01985919 · 150 participants
Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples
- NCT02016248 · 150 participants · NA
SBRT Boost for Unfavorable Prostate Cancer'
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI